Business Segments · Research and development expenses
Cardiovascular — Research and development expenses
Boston Scientific Cardiovascular — Research and development expenses increased by 11.3% to $375.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 37.9%, from $272.00M to $375.00M. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Research and development expenses shows an upward trend with a 18.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ4 2025
How to read this metric
Consistent or increasing investment is generally required to maintain a competitive edge in medical technology.
Detailed definition
Captures the investment in innovation, clinical trials, and product development specifically for the Cardiovascular segm...
Peer comparison
Standard R&D reporting for technology-driven healthcare companies.
Metric ID:
bsx_segment_cardiovascular_research_and_development_expensesHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $195.50M | $195.50M | $195.50M | $195.50M | $213.75M | $213.75M | $213.75M | $213.75M | $228.00M | $231.00M | $244.00M | $272.00M | $282.00M | $315.00M | $337.00M | $375.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +9.3% | +0.0% | +0.0% | +0.0% | +6.7% | +1.3% | +5.6% | +11.5% | +3.7% | +11.7% | +7.0% | +11.3% |
| YoY Change | — | — | — | — | +9.3% | +9.3% | +9.3% | +9.3% | +6.7% | +8.1% | +14.2% | +27.3% | +23.7% | +36.4% | +38.1% | +37.9% |
Range$195.50M – $375.00M
CAGR+19.0%
Avg YoY Growth+19.1%
Median YoY Growth+11.7%
Current Streak15+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — research and development expenses?
- Boston Scientific (BSX) reported cardiovascular — research and development expenses of $375.00M in Q4 2025.
- How has Boston Scientific's cardiovascular — research and development expenses changed year-over-year?
- Boston Scientific's cardiovascular — research and development expenses increased by 37.9% year-over-year, from $272.00M to $375.00M.
- What is the long-term trend for Boston Scientific's cardiovascular — research and development expenses?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — research and development expenses has grown at a 18.7% compound annual growth rate (CAGR), from $782.00M to $1.31B.
- What does cardiovascular — research and development expenses mean?
- The amount spent on research and development for cardiovascular products.